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The Process of Innovation
Mary Jo Veverka *
How do leading companies succeed in achieving high returns on their
technology investments despite growing financial constraints and
traditional barriers to successful commercialization?
The topic of innovation always draws high interest. My own experience spans across fifteen years of looking at product development issues;
five years in industry, and eleven years with Booz, Allen & Hamilton.
Increasingly, my work in the last few years has been specific to dealing
with issues of research and development ("R&D") management.
I plan to discuss some of the findings and conclusions drawn from
our work in helping clients deal with the issues of managing innovation
through to successful commercialization. These findings are drawn from
the broad-based industrial surveys we periodically take to better understand the issues and the companies' responses to those issues, and from
spending time with the leaders in the industry such as Dow and Merck to
assess what they do so successfully.
Technology investments have exploded in the last decade. Globallybased R&D expenditures over several successive decades, 1965-1985
have increased. This spiraling trend has continued in the United States
at almost twice the rate of inflation through the 1980s. The Japanese
have now surpassed the United States in R&D spending as a percentage
of gross national product ("GNP"). This first occurred in 1986, and they
have continued to outpace U.S. and other countries' spending. Other
countries are increasing their R&D investments as well.
With more and more money at stake, it is no surprise that CEOs are
concerned about how this money is being spent. In the pharmaceutical
industry, which is one of the leading spenders, the increases in worldwide
R&D demonstrate the challenges presented to these companies. All
companies are increasing not only their absolute R&D expenditures, but
their R&D expenditures as a percentage of sales. However, these greater
expenditures have not yielded an increase in the number of new products
being approved for the marketplace. Because of increased competition,
the risks attendant on these investments are also increasing. Moreover,
managing these investments - choosing the research focus, finding applications, taking a new technology to market - has become far more
complex.
Companies recognize that they are increasingly betting their futures
* Vice-President, Booz, Allen & Hamilton, New York, New York.
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on new technology. New technologies are dissolving natural divisions of
the value-added chain and eroding competitive positions based on these
very divisions.
I am going to share the results of several surveys that we have taken
to get a better sense of what issues leading companies are wrestling with
as they manage innovation. The first survey was taken in the late 1960s
to give us a basis for understanding the issues that management faces.
The second survey was taken in 1981. Seven hundred companies participated in that survey. It represented their collective experience on introducing over 13,000 new products over a five-year time span. We will be
planning another survey, probably next year, to update our perspective.
Later I am going to discuss what we have seen happen in the 1980s, as
companies have continued to wrestle with the issues related to
innovation.
Briefly, the survey results in 1981 show that during the early 1980s,
companies were counting on new products for growth. Over the five
years prior to 1981 new products had generated about 25% of the sales
growth. Companies were expecting that to increase by a third, to yield
about 33% of their growth over the next five years. Similarly, the portion of the total company profits generated by new products was expected to increase by 40%. To accomplish this, companies expected to
double the number of new products introduced. These expectations existed in all industries. Technology investments, in particular, have continued to grow in order to fuel this. I presume that if we look at the
results from the next survey, we will see that these companies have not
achieved their expectations with these increased technology investments.
Our analysis of the surveys identified several key new product practices and trends. An examination of the mix of new products introduced
yielded several important findings. First, additions to existing product
lines and improvements to existing products account for approximately
52% of all new product introductions. This conservative investment is
necessary to manage the product life cycle and keep existing products
viable. Another 30% are new product lines ,for the company and new
products for the world. These often become the firm's most successful
new products. Indeed, they accounted for approximately 60% of the
new products that were viewed as most successful. Despite the obvious
attractiveness of these categories, their variability of return is far greater.
Truly innovative products involve far higher risks. Thus, managers are
reluctant to put more investment into these areas.
Innovation risks are extremely high. For example, within the pharmaceutical industry very high attrition rates, lengthy development periods and escalating costs associated with new product development are
well documented. Anywhere from 2000 to 15,000 leads go into the applied research stage. At the development stage, when clinical trials are
undertaken, the fallout rate is about five out of six product ideas over a
period of six to eight years. The cost for development of a successful new
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product currently stands at about $140 million, factoring in failures, and
it is growing every year.
What are companies doing about this? The new product development process has been well-documented. Researching our own work in
this area, I discovered that we first documented this process back in the
1950s. The early documentation showed a six-step process which included idea/concept generation, screening and evaluating, business analysis, development, testing and commercialization. Today companies still
follow this process but lead it with a step which involves developing an
explicit new product strategy. Seventy-seven percent of the companies
surveyed in the early 1970s indicated that they were using this step. The
addition of this step has changed the nature of the beginning of the process. The first three steps, new product strategy development, codification of the idea concept generation, and screening and evaluating that
idea, have become a very closely linked set of steps in managing the innovative process for successful companies.
As a result, companies have shifted their resource allocation. Another way to look at this, given increasing R&D expenditures, is that
companies have increased front-end expenditures at a far greater rate
than expenditures later in the process. This appears to have improved
product selection. R&D spent on successful new products has grown
from about 30% historically to about 54% at the time of the second
survey.
The more sophisticated new product process has had a profound
effect on the number of ideas considered in developing one successful
new product. In the 1968 survey, on average, across all industries, it
took about fifty-eight new product ideas or concepts to yield one new
product in the marketplace. By 1981, this had dropped quite dramatically to about seven ideas. This begins to show you the impact and
power of the front-end strategy driving the whole new product development activity. Yet companies are not ranking their experience in terms
of successftil new products on the marketplace any better than in 1968.
This suggests that there are other factors also at work here, not just managing the overall R&D innovation process.
There is common agreement on the R&D commercialization objectives. It is clearly important to foster innovation. Increasingly companies are putting greater emphasis on winning the race to market. There
is much greater recognition today that getting to market early with innovation is a key element of competitive strategy and success in the marketplace. However, it is not only necessary to win that race, but also to
position products successfully against competitors in a local market.
Positioning products well requires marketplace input very early, in defining product features and how to proceed in the development process. It
is also being aware of what the competition is doing and how they are
proceeding. Ongoing competitive assessment increasingly needs to be
done in a global context as competition globalizes, particularly in tech-
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nology intensive industries. The emphasis on local markets cannot be
lost however. Some companies are beginning to think about globalization in the context of a single product which can be commercialized
worldwide. There remains an increasingly complex requirement to manage the innovation process to tailor products to local market needs. A
fourth objective is one of minimizing the resources required to achieve
the above goals.
In our work with clients over the last several years, we observed an
added set of management issues. Technology continues to change. Today there is a much-faster pace of change which needs to be factored in,
both from a strategy as well as a planning and execution perspective.
Many companies, as they have changed their strategies, have experienced
uneven new product pipelines. That in turn drives companies to go
outside of their organization to external sources of technology. We are
seeing more and more licensing and acquisitions, specifically for purposes
of sourcing technology. New sourcing strategies yield multiple funding
opportunities which increase the complexity of the decision-making process, and cause greater competition for scarce development resources.
Finally, as mentioned earlier, the global roll-out opportunities also add
complexity, particularly with regard to the organizational aspect. Companies are struggling with ways to improve bringing together the various
elements of the organization on a worldwide basis.
As we work with our clients in commercializing new technology, we
find that internal attitudes are a major contributor to the progression of
successful ideas. Typically, the approach to the technology assessment is
very much a "can-do" approach. This is promoted by the technology
champion who believes that technology can do anything and solves many
problems. Then the technologists encounter the marketing organization
which takes a very hard-nosed approach. One of the things that companies then wrestle with is how to balance the technology champion who
truly believes in the value of the technology against the marketing skeptic. A more successful approach is to flip those attitudes; get the technologists to take a hard-nosed approach, to be realistic about the true value
of the technology. How does it stack up against competition? How will
it be valued in the marketplace? Then challenge marketing to make this
work, to start small, find a success, and to move it to more successes in
the marketplace. Those companies who really manage innovation successfully balance the realistic assessment of the technology and the value
of the technology with the creativity of the marketing people who develop and position that product in the marketplace. The orientation of
how you manage the process and think about the performance requirements begins to change.
Product strategies must be developed in the context of the product,
the technology and the market life cycles. There are unique skills required at each stage of this cycle. For example, in the advanced materials area, one must look at the various dimensions of the customer's
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ability to pay for innovation, the value that innovation provides to the
customer and how the success requirements, from a technology and skill
base, change over the life cycle. The success requirements change as the
business evolves from the introduction of the material to processing refinements to much heavier reliance on application skills, and ultimately
to process scale. A company must understand the skill requirements
coupled with these customer and supplier economics. A breakdown at
any stage of this process can slow or stall the development of the
material.
A portfolio approach to project selection is also important and can
provide a bridge between the critical issue of management control requirements and the inherent risks associated with R&D technology.
Technology maturity and the specific technology emphasis required research, development or business support - define the various components of a corporate portfolio of technology applications and activities.
Companies need to look at their overall technology investments in the
context of the overall portfolio, to manage risk, technology evolution and
the allocation of these efforts.
There are several "Best Practices" for successful innovation and
technology commercialization. First is the need to make a long-term
commitment to support innovation in new product development. Second, companies need to implement company specific approaches, driven
by corporate objectives and strategies with a well-defined new product
strategy at the core. Companies have gone through various diversification stages. Now companies are focusing more on core businesses due to
the realization that making a company specific approach, based on experience and unique technical skills, is very important to continuing to
manage the innovation process successfully. Third, companies need to
capitalize on accumulated experience to achieve and maintain competitive advantage in the marketplace. That includes experience from the
total commercialization and marketing cycle, not just the accumulated
experience from technology. Finally, companies must establish an environment conducive to achieving new product and corporate objectives in
terms of management style, organizational design and the degree of top
management support.
In our 1968 survey, organizational problems were the key obstacles
to success in R&D management. By 1981 management practices and
planning attitudes had surfaced as the major deterrence. Lack of attention to new products and emphasis on short-term problems are something that has not disappeared in the 1980s. Also, from a management
practice standpoint, the need for more market research remains. We still
see many of the organizational problems. In fact, through the 1980s the
organizational problems have resurfaced. Today the combination of
globalization, the increasing pace of change, the niche strategies necessary in the competitive environment and the resulting complexity have
exacerbated the problems in the decision-making process.
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That leaves a number of management imperatives for the future.
Companies must aggressively pursue opportunities to accelerate product
development by focusing on where the development cycle can be shortened. This requires making timely decisions, within a strategic context.
It also requires an understanding of the trade-offs and the implications of
those decisions. Companies need to allow the decisions to be made at the
lowest appropriate level in the organization. New mechanisms will be
needed for improving the decision-making process. It also requires a renewed effort to ensure that an effective organization will support the decision-making process and ensure expeditious implementation.
The future R&D organization must concentrate on continuous selfimprovement ("CSI"), a critical building block of world-class performance. CSI is the ability of an organization to achieve continuously higher
levels of performance through a steady stream of seemingly small, internally generated improvements in methods, tools and procedures. R&D
leaders will energize and actualize their organizations for CSI through
changes in process and culture.

